Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High rates of vancomycin failure in methicillin-resistant Staphylococcus aureus (MRSA) infections have been increasingly reported over time. The primary objective of our study was to determine the impact of vancomycin exposure and outcomes in patients with MRSA bacteremia initially treated with vancomycin. METHODS: This was a single-center retrospective analysis of 320 patients with documented MRSA bacteremia initially treated with vancomycin from January 2005 through April 2010. Two methods of susceptibility, Etest and broth microdilution, were performed for all isolates to determine the correlation of susceptibility testing to patient outcomes. RESULTS: Among a cohort of 320 patients, more than half (52.5%) experienced vancomycin failure. Independent predictors of vancomycin failure in logistic regression included infective endocarditis (adjusted odds ratio [AOR], 4.55; 95% confidence interval [CI], 2.26-9.15), nosocomial-acquired infection (AOR, 2.19; 95% CI, 1.21-3.97), initial vancomycin trough <15 mg/L (AOR, 2.00; 95% CI, 1.25-3.22), and vancomycin minimum inhibitory concentration (MIC) >1 mg/L by Etest (AOR, 1.52; 95% CI, 1.09-2.49). With use of Classification and Regression Tree (CART) analysis, patients with vancomycin area under the curve at 24 h (AUC(24h)) to MIC ratios <421 were found to have significantly higher rates of failure, compared with patients with AUC(24h) to MIC ratios >421 (61.2% vs 48.6%; P = .038). CONCLUSIONS: In light of the high failure rates associated with this antimicrobial, optimizing the pharmacokinetic/pharmacodynamic properties of vancomycin by targeting higher trough values of 15-20 mg/L and AUC(24h)/MIC ratios ≥400 in selected patients should be considered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Lina, G., Piemont, Y., Godail-Gamot, F., Bes, M., Peter, M.-O., Gauduchon, V., Vandenesch, F., & Etienne, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313461 · Cited by 2,489 · cited 1×
“genes encoding Panton–Valentine leukocidin, and agr group and agr function were determined using previously described methods [24, 25].”
MethodSystem, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,310
Zhang, K., McClure, J.-A., Elsayed, S., Louie, T., & Conly, J. M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5026-5033.2005 · Cited by 1,037
Cosgrove, S. E., Qi, Y., Kaye, K. S., Harbarth, S., Karchmer, A. W., & Carmeli, Y. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502522 · Cited by 856
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
The emergence and evolution of methicillin-resistant Staphylococcus aureus
Hiramatsu, K., Cui, L., Kuroda, M., & Ito, T. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)02175-8 · Cited by 825
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citationRybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
Self-citationThe Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance
Kowalska-Krochmal, B., & Dudek-Wicher, R. (2021) · Pathogens · doi:10.3390/pathogens10020165 · Cited by 1,039
Novel antibody-antibiotic conjugate eliminates intracellular S. aureus
Lehar, S. M., Pillow, T., Xu, M., Staben, L., Kajihara, K. K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W. L., Hiroshi Morisaki, J., et al. (2015) · Nature · doi:10.1038/nature16057 · Cited by 838
van Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-12 · Cited by 639
“Despite its adoption, there are (10) limited data to suggest that maintenance of vancomycin trough values between 15 and 20 mg/liter improves outcomes (8, 10).”
BackgroundInfluentialHassoun, A., Linden, P. K., & Friedman, B. (2017) · Critical Care · doi:10.1186/s13054-017-1801-3 · Cited by 604
“Although vancomycin is the first-line antibiotic for MRSA bacteremia treatment, it has a relatively slow onset of bactericidal activity and poorly penetrates some tissues [68].”
Backgroundvan Hal, S. J., Lodise, T. P., & Paterson, D. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir935 · Cited by 512
“Twenty-three studies were excluded for the following reasons: no MIC data were presented against outcomes (11 studies) [16, 24, 27, 29, 30, 31, 33, 46, 51, 56, 57], inappropriate MIC testing methodology was used (3 studies) [13, 35, 44], case reports (2 studies) [11, 38], and nonrelevance (7 studies) [14, 18, 20, 22,…”
MethodClinical Management of Staphylococcus aureus Bacteremia: A Review
Holland, T. L., Arnold, C., & Fowler, V. G. (2014) · JAMA · doi:10.1001/jama.2014.9743 · Cited by 449
“Levine et al,45 1991 (openlabel RCT) Moderate 42 MRSA endocarditis (median [range] age of 32 [23-61] y); treatment with vancomycin alone (1 g every 12 h; n = 22) vs vancomycin (1 g every 12 h) plus rifampin (600 mg/d) (n = 20) Duration of bacteremia Median duration of 9 d for bacteremia for all patients; 7 (95% CI, 5…”
Blot, S. I., Pea, F., & Lipman, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.006 · Cited by 444
“Also for the vancomycin use in ICUpatients, insufficient drug concentrations were frequently observed and linked with poor clinical outcomes [72,73].”
BackgroundThe Nephrotoxicity of Vancomycin
Filippone, E., Kraft, W., & Farber, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.726 · Cited by 416
“As expected, however, VANT is associated with increased mortality(50) and length of stay in the ICU(60) and hospital.(50,61) Table 2 Current criteria for diagnosing and staging acute kidney injury”
BackgroundAre Vancomycin Trough Concentrations Adequate for Optimal Dosing?
Neely, M. N., Youn, G., Jones, B., Jelliffe, R. W., Drusano, G. L., Rodvold, K. A., & Lodise, T. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-13 · Cited by 392
“This probability of possibly toxic vancomycin exposure agrees well with four clinical studies that found early vancomycin trough concentrations of 20 mg/liter to be associated with subsequent nephrotoxicity in approximately 25 to 40% of patients (12, 13, 28, 29).”
BackgroundMethicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future
Rodvold, K. A., & McConeghy, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit614 · Cited by 358
“factor can serve as a predictor of success or failure for vancomycin therapy [17].”
BackgroundInnovative approaches to optimizing the delivery of vancomycin in individual patients
Pai, M. P., Neely, M., Rodvold, K. A., & Lodise, T. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.016 · Cited by 292
“However, at the upper end of the trough continuum, treatment failure again increased in patients with vancomycin trough concentrations N20 mg/L [20].”
BackgroundImproved Vancomycin Dosing in Children Using Area Under the Curve Exposure
Le, J., Bradley, J. S., Murray, W., Romanowski, G. L., Tran, T. T., Nguyen, N., Cho, S., Natale, S., Bui, I., Tran, T. M., et al. (2013) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318286378e · Cited by 262
“To optimize good clinical outcomes for invasive MRSA infections using pharmacokinetics (PK)–pharmacodynamics of vancomycin, studies in adults support targeting area under the curve (AUC) of the serum concentrations versus time over 24 hours to minimum inhibitory concentration (MIC) ratio of ≥400, which frequently corr…”
MethodOptimizing the Clinical Use of Vancomycin
Álvarez, R., López Cortés, L. E., Molina, J., Cisneros, J. M., & Pachón, J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03147-14 · Cited by 258
Identification and treatment of the Staphylococcus aureus reservoir in vivo
Surewaard, B. G. J., Deniset, J. F., Zemp, F. J., Amrein, M., Otto, M., Conly, J., Omri, A., Yates, R. M., & Kubes, P. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160334 · Cited by 254
Bosso, J. A., Nappi, J., Rudisill, C., Wellein, M., Bookstaver, P. B., Swindler, J., & Mauldin, P. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00168-11 · Cited by 252
Hamada, Y., Tokimatsu, I., Mikamo, H., Kimura, M., Seki, M., Takakura, S., Ohmagari, N., Takahashi, Y., Kasahara, K., Matsumoto, K., et al. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0607-8 · Cited by 248
“[25] reported that initial VCM trough \15 lg/ml was an independent predictor of VCM failure in patients with MRSA bacteremia.”
BackgroundInfluentialFinch, N. A., Zasowski, E. J., Murray, K. P., Mynatt, R. P., Zhao, J. J., Yost, R., Pogue, J. M., & Rybak, M. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01293-17 · Cited by 241
Self-citationLopez-Cortes, L. E., del Toro, M. D., Galvez-Acebal, J., Bereciartua-Bastarrica, E., Farinas, M. C., Sanz-Franco, M., Natera, C., Corzo, J. E., Lomas, J. M., Pasquau, J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit499 · Cited by 231
Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia
Holmes, N. E., Turnidge, J. D., Munckhof, W. J., Robinson, J. O., Korman, T. M., O'Sullivan, M. V. N., Anderson, T. L., Roberts, S. A., Warren, S. J. C., Gao, W., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01485-12 · Cited by 224
“(41) studied 320 patients with MRSA bacteremia using a composite endpoint of treatment failure (30-day mortality, persistent symptoms and signs of infection, and persistent bacteremia for 7 days).”
BackgroundThe Whole Price of Vancomycin: Toxicities, Troughs, and Time
Jeffres, M. N. (2017) · Drugs · doi:10.1007/s40265-017-0764-7 · Cited by 191
“Coadministration of nephrotoxic medications increases the risk of nephrotoxicity and is perhaps most often reported with aminoglycoside antibiotics [27, 29, 30].”
BackgroundMatsumoto, K., Takesue, Y., Ohmagari, N., Mochizuki, T., Mikamo, H., Seki, M., Takakura, S., Tokimatsu, I., Takahashi, Y., Kasahara, K., et al. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0599-4 · Cited by 184
Murray, K. P., Zhao, J. J., Davis, S. L., Kullar, R., Kaye, K. S., Lephart, P., & Rybak, M. J. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit112 · Cited by 178
“Secondary clinical outcomes included a survival analysis up to 90 days following the initial positive blood culture, inpatient mortality, hospital readmission within 30 days following discharge , and recurrence of MRSAB within 30 days of discharge or the last day of therapy, whichever occurred first.”
InfluentialSelf-citationPharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing
Onufrak, N. J., Forrest, A., & Gonzalez, D. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.06.015 · Cited by 170
Tsutsuura, M., Moriyama, H., Kojima, N., Mizukami, Y., Tashiro, S., Osa, S., Enoki, Y., Taguchi, K., Oda, K., Fujii, S., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05858-6 · Cited by 163
“Kullar 2011 [20] Retrospective America 2005– 2010 45–64 Median (IQR): Success 53 (45–64) Failure 54 (46–61) MRSA bacteremia (100%): Skin/wound, catheter-related, endocarditis, pneumonia, bone and joint, deep abscess, multiple sites, other.”
Lodise, T. P., Rosenkranz, S. L., Finnemeyer, M., Evans, S., Sims, M., Zervos, M. J., Creech, C. B., Patel, P. C., Keefer, M., Riska, P., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz460 · Cited by 161
Matsumoto, K., Oda, K., Shoji, K., Hanai, Y., Takahashi, Y., Fujii, S., Hamada, Y., Kimura, T., Mayumi, T., Ueda, T., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030489 · Cited by 176
“For the evaluation of vancomycin trough concentrations, effectiveness was assessed at a cut-off of 10 (two studies, n = 393) [22,23] or 15 μg/mL (eight studies, n = 849) [22–29], and safety was assessed through a comparison of 10–15 and <10 μg/mL (14 studies, n = 1637) [22,30–41], through a comparison of 15–20 and 10–…”
BackgroundResultInfluentialAntibody–Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections
Mariathasan, S., & Tan, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.12.008 · Cited by 146
Dhand, A., & Sakoulas, G. (2012) · F1000 Medicine Reports · doi:10.3410/m4-4 · Cited by 141
“Platelet microbicidal protein is believed to be an important innate host response mechanism that clears bacteria from the bloodstream when transient bacteremia occurs Kullar 2011[16] 2005-2010 Single center (US) 320 MRSA blood culture Etest Vancomycin failure was associated with Etest MIC>1 (AOR 1.”
BackgroundResultJacob, J. T., & DiazGranados, C. A. (2012) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.08.005 · Cited by 126
“Kullar et al.(20) Retrospective 2011 Yes Blood Etest 3”
InfluentialZelenitsky, S. A., Rubinstein, E., Ariano, R. E., Iacovides, H., Dodek, P., Mirzanejad, Y., & Kumar, A. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.10.015 · Cited by 116
van Hal, S. J., & Fowler, V. G. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit178 · Cited by 126
Peck, M., Rothenberg, M. E., Deng, R., Lewin-Koh, N., She, G., Kamath, A. V., Carrasco-Triguero, M., Saad, O., Castro, A., Teufel, L., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02588-18 · Cited by 108
Suzuki, Y., Kawasaki, K., Sato, Y., Tokimatsu, I., Itoh, H., Hiramatsu, K., Takeyama, M., & Kadota, J. (2012) · Chemotherapy · doi:10.1159/000343162 · Cited by 124
Men, P., Li, H.-B., Zhai, S.-D., & Zhao, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146224 · Cited by 118
“…398 BMD Holmes et al. (2013) All-cause mortality 17/108 21/74 / / 373 BMD Jung et al. (2014) Infection treatment failure / / 10/52 10/24 398.5 BMD Kullar et al. (2011) Infection treatment failure / / 107/221 61/99 421 BMD Moise et al. (2000) Infection treatment failure / / 7/32 16/21 345 BMD…”
BackgroundInfluentialChong, Y. P., Park, S., Kim, H. S., Kim, E. S., Kim, M., Park, K., Kim, S., Lee, S., Choi, S., Jeong, J., et al. (2013) · Medicine · doi:10.1097/md.0b013e318289ff1e · Cited by 125
“There has been a controversy as to whether high vancomycin MIC (MIC 91 mg/L) and hVISA phenotype of MRSA are associated with worse clinical outcomes, including mortality and vancomycin treatment failure.(2,25,28,34,39,51,54) Similarly, there has been a controversy as to whether high vancomycin MIC and hVISA phenotype…”
BackgroundInfluentialKullar, R., Casapao, A. M., Davis, S. L., Levine, D. P., Zhao, J. J., Crank, C. W., Segreti, J., Sakoulas, G., Cosgrove, S. E., & Rybak, M. J. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt294 · Cited by 99
Self-citationBlot, S. I., Koulenti, D., Akova, M., Bassetti, M., Waele, J. J. D., Dimοpoulos, G., Kaukonen, K., Martin, C., Montravers, P., Rello, J., et al. (2014) · Critical Care · doi:10.1186/cc13874 · Cited by 108
“Several investigators reported on pharmacokinetics of vancomycin in critically ill patients [5,6,15,16] but most studies are single centre designs and there is no insight in current practice - and therefore in pharmacokinetics variability - across ICUs.”
BackgroundWong, G. Y. M., Sime, F. B., Lipman, J., & Roberts, J. A. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-288 · Cited by 124
“Therapeutic drug monitoring (TDM), a tool traditionally used primarily to minimize toxicity in drugs with narrow therapeutic window or drugs with complex pharmacokinetics, is being increasingly used for antibiotic dose optimization in the attempt to improve attainment of pharmacokinetic/pharmacodynamic (PK/PD) targets…”
BackgroundJung, Y., Song, K., Cho, J. E., Kim, H.-S., Kim, K.-H., Kim, T. S., Choe, P. G., Chung, J., Park, W. B., Bang, J. H., et al. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.10.017 · Cited by 110
“Published findings regarding the association between vancomycin trough level and treatment outcome are inconsistent [4,6].”
BackgroundInfluentialThe role of antibiotic stewardship in limiting antibacterial resistance among hematology patients
Gyssens, I. C., Kern, W. V., Livermore, D. M., & on behalf of ECIL-4, A. J. V. O. E. (2013) · Haematologica · doi:10.3324/haematol.2013.091769 · Cited by 97
“Optimization of vancomycin dosing is achieved by using a loading dose (up to 35 mg/kg) and ensuring optimal trough levels of approximately 15 mg/L, either by twice-daily administration or continuous infusion, in order to achieve an (AUC)0-24: MIC ratio of more than 400, which correlates with positive outcomes in patie…”
BackgroundPotentials of nanotechnology in treatment of methicillin-resistant Staphylococcus aureus
Gao, Y., Chen, Y., Cao, Y., Mo, A., & Peng, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113056 · Cited by 107
Rybak, M. J., Vidaillac, C., Sader, H. S., Rhomberg, P. R., Salimnia, H., Briski, L. E., Wanger, A. R., & Jones, R. N. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00448-13 · Cited by 101
“fections, such as complicated bacteremia (3, 8).”
Self-citationColin, P. J., Allegaert, K., Thomson, A. H., Touw, D. J., Dolton, M. J., de Hoog, M., Roberts, J. A., Adane, E. D., Yamamoto, M., Buelga, D. S., et al. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0727-5 · Cited by 106
Casapao, A. M., Lodise, T. P., Davis, S. L., Claeys, K. C., Kullar, R., Levine, D. P., & Rybak, M. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03970-14 · Cited by 101
“Although vancomycin is considered first-line therapy, failure rates with vancomycin for the treatment of IE are exceedingly high (1).”
BackgroundSelf-citationNovel LC–MS/MS method for plasma vancomycin: Comparison with immunoassays and clinical impact
Oyaert, M., Peersman, N., Kieffer, D., Deiteren, K., Smits, A., Allegaert, K., Spriet, I., Eldere, J. V., Verhaegen, J., Vermeersch, P., et al. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.12.012 · Cited by 89
Barber, K. E., Ireland, C. E., Bukavyn, N., & Rybak, M. J. (2014) · Infectious Diseases and Therapy · doi:10.1007/s40121-014-0023-0 · Cited by 90
“aureus (VISA), heterogeneous VISA (hVISA), or DAP non-susceptible (DNS) [3–10].”
BackgroundSelf-citationKumar, A. (2014) · Virulence · doi:10.4161/viru.26913 · Cited by 86
“aureus bacteremia reported fewer vancomycin treatment failures in those who had AUC 24 /MIC values ≥421.(220) In another retrospective study in patients with MRSA pneumonia, better microbiological and clinical outcomes in patients who had vancomycin AUC 24 / MIC values ≥400.”
BackgroundKullar, R., Davis, S. L., Taylor, T. N., Kaye, K. S., & Rybak, M. J. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2011.01017.x · Cited by 86
Self-citationBakke, V. D., Sporsem, H., Lippe, E. V. D., Nordøy, I., Lao, Y. E., Nyrerød, H. C., Sandvik, L., Hårvig, K. R., Bugge, J. F., & Helset, E. (2017) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12897 · Cited by 86
“Although the reason for this creep is debatable, it has caused clinical concern in regards to the use of vancomycin.(4,5) Focus on appropriate utilization of the drug has intensified.”
BackgroundCasapao, A. M., Leonard, S. N., Davis, S. L., Lodise, T. P., Patel, N., Goff, D. A., LaPlante, K. L., Potoski, B. A., & Rybak, M. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00380-13 · Cited by 85
“Failure of vancomycin treatment was defined by the following criteria: (i) nonresolving bacteremia for at least 7 days while on vancomycin (17, 20, 28); (ii) new onset or worsening of signs or symptoms of infection while on vancomycin therapy (7, 28); (iii) either change of MRSA intravenous antibiotic or addition to v…”
MethodSelf-citationMaking the change to area under the curve–based vancomycin dosing
Heil, E. L., Claeys, K. C., Mynatt, R. P., Hopkins, T. L., Brade, K. D., Watt, I., Rybak, M. J., & Pogue, J. M. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp180034 · Cited by 86
Self-citationOptimizing Antimicrobial Drug Dosing in Critically Ill Patients
Póvoa, P. M. S. R., Moniz, P., Gonçalves-Pereira, J., & Coelho, L. (2021) · Microorganisms · doi:10.3390/microorganisms9071401 · Cited by 91
“However, the current formulas of estimating GFR risk imprecise estimations for AUC determinations [78], especially in the presence of significant interindividual variability of exposure profiles [79,80].”
BackgroundCampassi, M. L., Gonzalez, M. C., Masevicius, F. D., Vázquez, A., Moseinco, M. C., Navarro, N., Previgliano, L., Rubatto, N. P., Benites, M. H., Estenssoro, E., et al. (2014) · Revista Brasileira de Terapia Intensiva · doi:10.5935/0103-507x.20140003 · Cited by 85
“Hospital length of stay (days) 7 [5-11] 8 [5-15] 0.”
BackgroundPharmacokinetic and Pharmacodynamic Issues for Antimicrobial Therapy in Patients With Cancer
Theuretzbacher, U. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis210 · Cited by 85
“A growing body of evidence indicates that, for other common antibacterial classes, such as vancomycin, linezolid, daptomycin , and quinolones, individualized higher dosages based on TDM may be required.”
MethodInfluentialSteinmetz, T., Eliakim‐Raz, N., Goldberg, E., Leibovici, L., & Yahav, D. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.04.003 · Cited by 90
Downes, K. J., Hahn, A., Wiles, J. R., Courter, J. D., & Vinks, A. A. T. M. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.11.006 · Cited by 92
“In adults with MRSA infections, an AUC0–24/MIC of >400 has been associated with improved clinical outcomes [50,51].”
BackgroundPeritoneal GATA6+ macrophages function as a portal for Staphylococcus aureus dissemination
Jorch, S. K., Surewaard, B. G. J., Hossain, M., Peiseler, M., Deppermann, C., Deng, J., Bogoslowski, A., van der Wal, F., Omri, A., Hickey, M. J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127286 · Cited by 77
“This, and the observation that clinical infection relapse after antibiotic use is not uncommon, suggest that bacteria may hide inside cells as an evasion mechanism that facilitates their resistance to the immune response and antibiotics (5).”
BackgroundHirai, K., Ishii, H., Shimoshikiryo, T., Shimomura, T., Tsuji, D., Inoue, K., Kadoiri, T., & Itoh, K. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000346 · Cited by 76
Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range.
Abdul-Aziz, M. H., Brady, K., Cotta, M. O., & Roberts, J. A. (2022) · PubMed · doi:10.1097/ftd.0000000000000940 · Cited by 48
Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond
Holmes, N. E., Tong, S. Y. C., Davis, J. S., & van Hal, S. J. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1397040 · Cited by 94
Long-term effects of an antimicrobial stewardship programme at a tertiary-care teaching hospital
Cook, P., & Gooch, M. D. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.11.006 · Cited by 78
Kalil, A. C., Klompas, M., Haynatzki, G. R., & Rupp, M. E. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003912 · Cited by 80
“In the case of vancomycin, these include increased risk of clinical failure if the drug is underdosed, increased risk of nephrotoxicity if the drug is overdosed and central venous catheter complications such as bloodstream infections and thromboembolic disease.(12) In light of the renewed controversy and public health…”
BackgroundVancomycin dosing, monitoring and toxicity: Critical review of the clinical practice
Zamoner, W., Prado, I. R. S., Balbi, A. L., & Ponce, D. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13066 · Cited by 82
Guérillot, R., da Silva, A. G., Monk, I. R., Giulieri, S. G., Tomita, T., Alison, E., Porter, J., Pidot, S. J., Gao, W., Peleg, A. Y., et al. (2018) · mSphere · doi:10.1128/msphere.00550-17 · Cited by 74
Hirai, K., Ihara, S., Kinae, A., Ikegaya, K., Suzuki, M., Hirano, K., & Itoh, K. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000270 · Cited by 67
“The recent recommendation has suggested that the target trough concentrations should be up to 15–20 mcg/mL(2,3) to achieve the area under the concentration–time curve (AUC) to the minimal inhibitory concentration (MIC) (AUC/MIC) of $400.(4,5) The recommendations for target trough concentrations are derived from a popu…”
BackgroundHorey, A., Mergenhagen, K. A., & Mattappallil, A. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r158 · Cited by 68
Model-Informed Precision Dosing of Antibiotics in Pediatric Patients: A Narrative Review
Abdulla, A., Edwina, A. E., Flint, R. B., Allegaert, K., Wildschut, E. D., Koch, B. C. P., & de Hoog, M. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.624639 · Cited by 71
Edwards, B., Milne, K., Lawes, T., Cook, I., Robb, A., & Gould, I. M. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05520-11 · Cited by 65
“The likelihood of attaining this is considerably decreased as the MIC approaches 2 mg/liter, with the associated nephrotoxicity one would expect from the larger doses required (14).”
BackgroundDalton, B., Rajakumar, I., Langevin, A., Ondro, C., Sabuda, D. M., Griener, T. P., Dersch‐Mills, D., & Rennert‐May, E. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.10.029 · Cited by 73
Optimizing Antimicrobial Therapy of Sepsis and Septic Shock: Focus on Antibiotic Combination Therapy
Vázquez‐Grande, G., & Kumar, A. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398742 · Cited by 82
Park, K., Chong, Y. P., Kim, S., Lee, S., Choi, S., Lee, M. S., Jeong, J., Woo, J. H., & Kim, Y. S. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.07.026 · Cited by 63
Ocampos-Martinez, E., Penaccini, L., Scolletta, S., Abdelhadii, A., Devigili, A., Cianferoni, S., Backer, D. D., Jacobs, F., COTTON, F. J., Vincent, J., et al. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.12.008 · Cited by 62
Song, K., Kim, H. B., Kim, H.-S., Lee, M. J., Jung, Y., Kim, G., Hwang, J.-H., Kim, K.-H., Kim, M., Kim, C.-J., et al. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.09.010 · Cited by 67
“his was because of their retrospective nature and the long study eriods involved (usually over 5 years) [5,8,9,12,13].”
InfluentialOptimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs
Lê, J., & Bradley, J. S. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1128 · Cited by 62
Empiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance
Liang, S. Y., & Kumar, A. (2015) · Current Infectious Disease Reports · doi:10.1007/s11908-015-0493-6 · Cited by 76
Hagihara, M., Wiskirchen, D. E., Kuti, J. L., & Nicolau, D. P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05473-11 · Cited by 64
“Four clinical isolates (two MRSA isolates [vancomycin MICs, 0.5 and 2.0 g/ml], a heterogeneous vancomycin-intermediate S. aureus [hVISA] isolate [MIC, 2.0 g/ml], and a vancomycinintermediate S. aureus [VISA] isolate [MIC, 8.0 g/ml]) were evaluated in an in vitro pharmacodynamic model with a starting inoculum of 106 or…”
BackgroundInfluentialPharmacokinetic/Pharmacodynamic Determinants of Vancomycin Efficacy in Enterococcal Bacteremia
Jumah, M. T. B., Vasoo, S. S., Menon, S., De, P. P., Neely, M. N., & Teng, C. B. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01602-17 · Cited by 61
“Previous preclinical and clinical studies suggested that the AUC/MIC ratio is the pharmacodynamic parameter best associated with vancomycin effectiveness (6, 7).”
BackgroundMogle, B. T., Steele, J. M., Seabury, R. W., Dang, U. J., & Kufel, W. D. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.08.024 · Cited by 63
Guo, T., van Hest, R. M., Roggeveen, L. F., Fleuren, L. M., Thoral, P., Bosman, R. J., van der Voort, P. H. J., Girbes, A. R. J., Mathôt, R. A. A., & Elbers, P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02543-18 · Cited by 64
Holland, T. L., & Fowler, V. G. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir275 · Cited by 61
“Kullar et al [2] 2011 ,1 vs $1 Etest and BMD MRSA bacteremia Retrospective cohort Higher rate of vancomycin failure with higher MIC”
BackgroundInfluentialGould, I. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.04.006 · Cited by 60
Gudiol, F., Aguado, J. M., Almirante, B., Bouza, E., Cercenado, E., Domínguez, M. Á., Gasch, O., Lora-Tamayo, J., Miró, J. M., Palomar, M., et al. (2015) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2015.03.015 · Cited by 78
“-lactams against MRSA, 183,184 including VISA isolates .”
Felton, T., Hope, W. W., & Roberts, J. A. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.04.007 · Cited by 73
“Penicillins fT>MIC 40-50% fT>MIC (Lodise et al. 2007) (Turnidge 1998) (Roberts et al. 2010) (Blondiaux et al. 2010) Vancomycin fAUC0-24/MIC AUC0-24/MIC 86-460 (Moise-Broder et al. 2004) (Zelenitsky et al. 2013) (Kullar et al. 2011)”
Tongsai, S., & Koomanachai, P. (2016) · BMC Research Notes · doi:10.1186/s13104-016-2252-7 · Cited by 63
“There was two exceptions [17, 33], however, with success rates ranging from 24 to 82 % and 39 to 87 % for high and low trough groups, respectively.”
BackgroundUsman, M., & Hempel, G. (2016) · SpringerPlus · doi:10.1186/s40064-016-1778-4 · Cited by 58
“Background Vancomycin (VAN), a glycopeptide antibiotic is used against infections caused by Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA) (Van Bambeke 2004; Lundstrom and Sobel 2004; Wilhelm and Estes 1999; Kullar et al. 2011).”
BackgroundHale, C. M., Seabury, R. W., Steele, J. M., Darko, W., & Miller, C. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190016642692 · Cited by 59
Park, K.-H., Kim, E. S., Kim, H. S., Park, S.-J., Bang, K. M., Park, H. J., Park, S.-Y., Moon, S. M., Chong, Y. P., Kim, S.-H., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks131 · Cited by 57
Hall, R. G., Hazlewood, K. A., Brouse, S. D., Giuliano, C. A., Haase, K. K., Frei, C. R., Forcade, N. A., Bell, T., Bedimo, R., & Álvarez, C. A. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-12 · Cited by 55
“A vancomycin trough greater than 20 mcg/ml was based on previous observations of increased rates of nephrotoxicity compared with troughs of 15-20 mcg/ml [10].”
BackgroundMethodResultInfluentialMahajan, S. N., Shah, J. N., Hachem, R. Y., Tverdek, F. P., Adachi, J. A., Mulanovich, V. E., Rolston, K. V. I., RAAD, I. I., & Chemaly, R. F. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0029 · Cited by 65
“A similar failure rate was reported in a recent retrospective single-center study of 320 patients [24] with documented MRSA BSIs who were initially treated with vancomycin between 2005 and 2010.”
ResultLeroy, O., Meybeck, A., Sarraz-Bournet, B., D’Elia, P., & Legout, L. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283501853 · Cited by 63
kamel, A. B., Bourguignon, L., Marcos, M., Ducher, M., & Goutelle, S. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000359 · Cited by 56
Individualized Empiric Vancomycin Dosing in Neonates Using a Model-Based Approach
Frymoyer, A. R., Stockmann, C. R., Hersh, A. L., Goswami, S., & Keizer, R. J. (2017) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/pix109 · Cited by 59
Smit, C., Wasmann, R. E., Goulooze, S. C., Wiezer, M. J., van Dongen, E. P. A., Mouton, J. W., Brüggemann, R. J. M., & Knibbe, C. A. J. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14144 · Cited by 54
Management of Staphylococcus aureus Bloodstream Infections
Kimmig, A., Hagel, S., Weis, S., Bahrs, C., Löffler, B., & Pletz, M. W. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.616524 · Cited by 61
A Randomized Trial of Loading Vancomycin in the Emergency Department
Rosini, J. M., Laughner, J., Levine, B. J., Papas, M. A., Reinhardt, J. F., & Jasani, N. B. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014556813 · Cited by 61
Hot topics in the diagnosis and management of skin and soft-tissue infections
Esposito, S., Bassetti, M., Bonnet, É., Bouza, E., Chan, M., Simone, G. D., Dryden, M., Gould, I. M., Lye, D. C., Saeed, K. B. A., et al. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.011 · Cited by 53
“This has been linked to increased mortality in MRSA bacteraemia [23].”
BackgroundJousselin, A., Kelley, W. L., Barras, C., Lew, D. P., & Renzoni, A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00220-13 · Cited by 55
Hagihara, M., Sutherland, C. A., & Nicolau, D. P. (2012) · Journal of Chromatographic Science · doi:10.1093/chromsci/bms128 · Cited by 52
Metadata
- Authors
- Kullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Wayne State University (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-01
- Volume
- 52
- Issue
- 8
- Pages
- 975-981
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2099365065
- Semantic Scholar
- ed3c7f78a7e345dd4578c14051be67b5da32fd88
- Cited by
- 463
- References
- 44
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 15 · 2023: 15 · 2022: 22 · 2021: 37 · 2020: 33 · 2019: 40 · 2018: 27 · 2017: 26 · 2016: 30 · 2015: 37 · 2014: 43 · 2013: 57 · 2012: 45
- FWCI
- 34.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, methicillin-resistant Staphylococcus aureus, MRSA bacteremia, pharmacokinetic/pharmacodynamic targets, AUC/MIC ratio, trough concentration, infective endocarditis, nosocomial infections, antimicrobial susceptibility testing, E-test, broth microdilution
- MeSH terms
- Anti-Bacterial Agents, Humans, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Staphylococcal Infections, Vancomycin, Bacteremia, Treatment Outcome, Guidelines as Topic, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.